Thanh Dellinger, M.D., is an academic gynecologic oncologist at City of Hope, with specialized training in robotic-assisted (minimally invasive) surgery for uterine and cervical cancer, and advanced cytoreductive surgery for ovarian cancer. Additionally, Dr. Dellinger has specialized training in PIPAC, a novel drug delivery method for recurrent ovarian cancer patients, and currently leads the first in U.S. clinical trial evaluating this novel therapy (NCT04329494), as well as leads PIPAC training courses. Dr. Dellinger’s research focus is in ovarian and uterine cancer, and she has co-authored over fifty papers on HIPEC, PIPAC, and novel therapies and molecular pathways in ovarian and uterine cancer. Her current clinical research focuses on optimizing regional therapies in ovarian cancer patients. Dr. Dellinger received her medical degree at University of California Irvine, followed by a residency at Penn State University and Gynecologic Oncology fellowship at University of California Irvine Medical Center.